Skip to NavigationSkip to content

psoriatic arthritis

Janssen's Tremfya shows skin clearance benefit for psoriatic arthritis patients in two Phase 3 studies

Janssen has revealed data from two Phase 3 trials for Tremfya (guselkumab), showing improvement in skin clearance and symptoms in adult patients with active psoriatic arthritis (PsA).

The DISCOVER-1 study examined the efficacy of Tremfya in biologic-naïve patients or those who have previously received anti-TNF alpha biologics, while the DISCOVER-2 study looked at only biologic-naïve patients, while also assessing radiographic progression of joint damage.  

AbbVie's Rinvoq hits target in psoriatic arthritis sub-population at Phase 3

AbbVie has unveiled new Phase 3 data on its selective and reversible JAK inhibitor Rinvoq (upadacitinib) in the treatment of active psoriatic arthritis in adults who have responded inadequately or are intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).

The results revealed that 71% of patients receiving 15mg Rinvoq and 79% receiving 30mg achieved an ACR20 response after 12 weeks of treatment compared to 36% with placebo, meeting the trial’s primary endpoint.

Novartis' Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs and symptoms of psoriatic arthritis in patients with and without enthesitis, a sub-group representing around 30-50% of the total incidence of the disease.

Pooled two-year data from a pair of Phase 3 studies indicated that patients taking Cosentyx achieved complete resolution of enthesitis at a faster rate than those receiving placebo, while improvement in signs and symptoms of the condition, measured on the American College of Rheumatology 50

NICE recommends Eli Lilly's psoriatic arthritis drug

Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option in England and Wales for adults with active psoriatic arthritis (PsA), after inadequate response to DMARDs (disease modifying antirheumatic drugs).

Ixekizumab was granted EU marketing authorisation in January 2018. The efficacy and safety of ixekizumab was determined from the findings of two randomized, double-blind, placebo-controlled Phase 3 studies involving 780 patients.

Pfizer's Xeljanz scores EU approval for active psoriatic arthritis

Pfizer has announced that the European Commission (EC) has approved Xeljanz in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.

Eli Lilly's Taltz get EU approval in psoriatic arthritis subgroup

Eli Lilly has revealed that its IgG4 monoclonal antibody Taltz (ixekizumab) has been awarded marketing approval from the European Commission for the treatment of active psoriatic arthritis (PsA) in patients for which disease-modifying anti-rheumatic drug (DMARD) therapies are not an option or have proved ineffective, when used alone or in combination with methotrexate.

FDA approves Pfizer's Xeljanz for psoriatic arthritis

Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

Celgene's Otezla hits primary endpoint in psoriatic arthritis study

Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment met its primary endpoint, improving ACR20 response at week 16 versus placebo in patients suffering from active psoriatic arthritis.

Novartis reveals positive three-year efficacy data for psoriatic arthritis drug

Novartis has claimed that its Cosentyx (secukinumab) treatment is now the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate three-year efficacy in patients with psoriatic arthritis (PsA).

The manufacturer noted that 77% of PsA patients reported an ACR 20 response (American College of Rheumatology response criteria) when treated with the drug in the first year of a three-year extension study, itself a continuation of a previous two-year study.

Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial

Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial evaluated the efficacy of Xeljanz for the treatment of psoriatic arthritis in a bid to expand the regulatory approval for the drug.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches